Sport & Auto
- About Future
- Digital Future
- Cookies Policy
- Terms & Conditions
- Investor Relations
- Contact Future
Hyper-aggressive position for the sprint lead-out
How much air pressure pros use at the Tour de France
National theme bike for Tour's lone Japanese rider
Teams bringing multiple models of sponsor bikes
Mikel Astarloza and his teammates
Counter-analysis pending for Tour stage winner Astarloza's positive EPO test, says team
Team Euskaltel-Euskadi denied receiving notification that counter-analysis confirmed Mikel Astarloza's positive test for blood booster Erythropoietin (EPO). Various media sources have announced in recent days the counter-analysis of a urine sample taken June 26 also tested positive.
"Right now we do not know one way or the other," team manager Miguel Madariaga told Marca.com. "We know that the counter-analysis has been done, and that the laboratory in Madrid has sent it to the UCI [International Cycling Union - ed.], and the UCI now has to decide."
Euskaltel hasn't received notification of the result, he said. If the UCI announces a positive counter-analysis on the "B sample" Spain's Astarloza will have 10 days to appeal.
Astarloza tested positive for EPO on June 26, but the UCI only announced the result July 31. He rode the Tour de France and won the mountain stage to Bourg-Saint-Maurice, July 1.
The UCI temporarily suspended Astarloza, 29, when it announced the result. The team said that it considered him innocent until proven guilty.
Astarloza was the second rider from the Basque team to test positive that month after Iñigo Landaluze.
Follow Cyclingnews on Twitter for the very latest coverage of events taking place in the cycling world - twitter.com/cyclingnewsfeed